Results for this period
Third quarter1 January 2026 to 30 September 2026Non-consolidated (individual)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Research and development expenses decreased by ¥24.774 million from the same period of the previous year, mainly because the amount of clinical development-related expenses recorded decreased. In the drug discovery support business, revenue from research support provided to pharmaceutical companies declined, while revenue related to biosimilars increased.
Not applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 January 2026 to 30 September 2026 |
| Net Sales | 406 Millions of yen (YoY +10.0%) |
| Operating profit | -736 Millions of yen |
| Ordinary income | -737 Millions of yen |
| Profit attributable to owners of the parent | -739 Millions of yen |
| Net income per share | (¥9.76) |
| Equity ratio | End of the current fiscal period 82 / End of previous period 64.1 |
| Total assets | 1,833 Millions of yen |
| Net assets | 1,503 Millions of yen |
| Full-year earnings forecast | Net Sales 600 Millions of yen / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed |
| Revision to Earnings Forecast | Drug discovery support business revenue: ¥600 million → No change (drug discovery support business revenue: ¥600 million) |
| Annual Dividend Forecast | 0 Yen → 0 Yen |
| Segment revenue | Drug Discovery Business ¥0 thousand, Drug Discovery Support Business ¥406,975 thousand |
| Segment profit | Drug Discovery Business ¥-561,423 thousand, Drug Discovery Support Business ¥235,770 thousand |
| Depreciation and amortization | ¥7,667 thousand |
| Impairment loss | Not applicable |
| Breakdown of extraordinary income (loss) | No extraordinary income or extraordinary losses were recorded for the current fiscal year |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 81,863,700 |
| Treasury Shares at Period-End | 22,819 |
| Factors Behind Changes in Business Performance | Research and development expenses decreased by ¥24.774 million from the same period of the previous year, mainly because the amount of clinical development-related expenses recorded decreased. In the drug discovery support business, revenue from research support provided to pharmaceutical companies declined, while revenue related to biosimilars increased. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Research and development expenses decreased by ¥24.774 million from the same period of the previous year, mainly because the amount of clinical development-related expenses recorded decreased, resulting in narrower operating, ordinary and quarterly net losses. In the drug discovery support business, revenue from research support provided to pharmaceutical companies declined, while revenue related to biosimilars increased.